Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06103123
Other study ID # MYCOVACC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 23, 2023
Est. completion date April 23, 2025

Study information

Verified date October 2023
Source Cardiology Research UBC
Contact Jenny Petterson, MSc
Phone 604-875-5104
Email jenny.petterson@vch.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection. The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date April 23, 2025
Est. primary completion date March 23, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Inclusion criteria for vaccine associated myocarditis/pericarditis. 1. COVID-19 vaccination within previous 42 days. AND 2. At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5). OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5). OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI). AND 3. At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5): 1. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation. 2. Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB). 3. Cardiac MRI abnormality. 4. Echocardiographic abnormality. 5. New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry. 6. Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer. 7. Physical examination pericardial friction rub or pulsus paradoxus. 8. Pericardial fluid or inflammation by imaging (echo, MRI, or CT). 9. Enlarged heart on chest radiograph. AND 4. No alternative cause of presentation. e.g. infectious or autoimmune myocarditis. - Inclusion criteria for COVID-19 associated myocarditis/pericarditis 1. COVID-19 infection within the previous 42 days. AND 2. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis. AND 3. No alternative cause of presentation. Inclusion criteria alternative etiology myocarditis. 1. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis. AND 2. No alternative cause of presentation. Exclusion Criteria: - For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker. - Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction.

Study Design


Intervention

Diagnostic Test:
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
Other:
Baseline Quality of Life questionnaire
Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study

Locations

Country Name City State
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Cardiology Research UBC

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators) Including any of:
Death from any cause.
Ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia).
Heart block (type II or type III block).
Heart failure (national guideline criteria).
Left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] <55%).
Cardiac tamponade.
From date of vaccination and up to 3 years
Primary Recovery of cardiac function in patients with previously documented abnormal cardiac function Patients with Left Ventricular Ejection Fraction (LVEF)<55% during anytime at baseline, with LVEF increase by 5% from worst baseline measurement Through study completion, an average of 3 years
Primary Quality of life using validated instruments at baseline, 3 months, 12 months, and annually Quality of life: EQ-5D-5L questionnaire for adults or EQ-5D-Y questionnaire for children. Through study completion, an average of 3 years
Primary Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually Depression and anxiety data: PHQ-9 and GAD-7. Through study completion, an average of 3 years
Primary Physical activity using validated instruments at baseline, 3 months, 12 months, and annually Physical activity: International Activity Questionnaire. Through study completion, an average of 3 years
Secondary Individual components of primary composite endpoint at 30 days and 42 days post mRNA COVID-19 vaccination? From date of vaccination for up to three years
Secondary Rate of atrial arrhythmias after mRNA COVID-19 vaccination? From date of vaccination for up to three years
Secondary Rate of all-cause and cardiovascular mortality after mRNA COVID-19 vaccination? From date of vaccination for up to three years
Secondary Rate of all-cause and cardiovascular hospitalization after mRNA COVID-19 vaccination? From date of vaccination for up to three years
Secondary Rate of recurrence of myocarditis/pericarditis after mRNA COVID-19 vaccination? From date of vaccination for up to three years
Secondary Rate of constrictive pericarditis after mRNA COVID-19 vaccination? From date of vaccination for up to three years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911386 - Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Not yet recruiting NCT04085718 - FDG-PET/CT Images Comparing to MRI and Endomyocardial Biopsy in Myocarditis
Enrolling by invitation NCT05610423 - Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway
Active, not recruiting NCT05195645 - AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS Phase 2
Recruiting NCT05184114 - Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance N/A
Recruiting NCT04612296 - The Heart Hive - Cardiomyopathy Study
Recruiting NCT04673409 - CMR Imaging of Autoimmune Diseases
Recruiting NCT05295290 - A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. Phase 4
Completed NCT03777839 - PET-FDG in Myocarditis
Completed NCT06447935 - Acute Eosinophilic Myocarditis International Registry
Not yet recruiting NCT05125965 - Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy N/A
Active, not recruiting NCT04444128 - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting NCT06158698 - CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine Phase 3
Recruiting NCT05282498 - Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)
Recruiting NCT05288426 - Myocarditis Post Vaccination or Multi System Inflammatory Syndrome
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT06116084 - Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine N/A
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Recruiting NCT06409585 - Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

External Links